Late onset imatinib-induced Stevens–Johnson syndrome-Reference-Cited by-同舟云学术

Late onset imatinib-induced Stevens–Johnson syndrome

Published:2014-01-07 Issue:6 Volume:20 Page:476-478
ISSN:1078-1552
Container-title:Journal of Oncology Pharmacy Practice
language:en
Short-container-title:J Oncol Pharm Pract

Author:

Bois Evan¹,Holle Lisa M²,Farooq Umar³

Affiliation:

1. Rite Aid, Waterville, ME, USA

2. Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA

3. Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA

Abstract

Imatinib, a BCR-ABL tyrosine kinase inhibitor, is known to cause mild to moderate cutaneous reactions in up to approximately 20% of patients. It rarely causes severe reactions, such as Stevens–Johnson syndrome, which can be life threatening. Typically, these rashes occur within two months of initiating therapy. We report a case of Stevens–Johnson syndrome induced by imatinib after several years of therapy, but later successfully was treated with nilotinib therapy.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1078155213518226

Reference10 articles.

1. Stevens-Johnson Syndrome Induced by Combination of Imatinib and Allopurinol

2. Imatinib-induced Stevens–Johnson syndrome: recurrence after re-challenge with a lower dose

3. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients

4. Severe Adverse Cutaneous Reactions to Drugs

5. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy;Journal of Inflammation Research;2024-04

2. Bosutinib-Induced Stevens-Johnson Syndrome and Evidence of Tolerance to a Structurally Dissimilar Tyrosine Kinase Inhibitor;Cureus;2022-03-18

3. Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review);Oncology Reports;2020-12-24

4. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies;Cancer Management and Research;2018-05

5. Blistering and Skin Fragility Due to Imatinib Therapy: Loss of Laminin and Collagen IV as a Possible Cause of Cutaneous Basement Membrane Instability;The American Journal of Dermatopathology;2018-05